Evidence map›Paper›PMID 40548679›Full record

Trial reportJournal of cardiovascular electrophysiology2025

Efficacy of additional ExTRa Mapping-guided substrate ablation beyond pulmonary vein isolation in persistent atrial fibrillation: The ROTATE trial.

Tetsuma Kawaji, Takanori Aizawa, Satoshi Shizuta, Saki Yamano, Misaki Naka, Bingyuan Bao, Shun Hojo, Shintaro Matsuda, Masashi Kato, Takafumi Yokomatsu and 1 more

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of cardiovascular electrophysiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Characteristics of rotational activation identified by the novel high-density ExTRa Mapping system.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2026
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Tetsuma KawajiDepartment of Cardiology, Mitsubishi Kyoto Hospital, Kyoto.ORCID 0000-0001-9929-902X
Takanori AizawaDepartment of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto.
Satoshi ShizutaDepartment of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto.ORCID 0000-0003-4587-9031
Saki YamanoDepartment of Cardiology, Mitsubishi Kyoto Hospital, Kyoto.
Misaki NakaDepartment of Cardiology, Mitsubishi Kyoto Hospital, Kyoto.
Bingyuan BaoDepartment of Cardiology, Mitsubishi Kyoto Hospital, Kyoto.
Shun HojoDepartment of Cardiology, Mitsubishi Kyoto Hospital, Kyoto.
Shintaro MatsudaDepartment of Cardiology, Mitsubishi Kyoto Hospital, Kyoto.
Masashi KatoDepartment of Cardiology, Mitsubishi Kyoto Hospital, Kyoto.
Takafumi YokomatsuDepartment of Cardiology, Mitsubishi Kyoto Hospital, Kyoto.ORCID 0000-0002-5700-5422
Shinji MikiDepartment of Cardiology, Mitsubishi Kyoto Hospital, Kyoto.

Funding

The authors received no specific funding for this work.
6 · The paper itself

Abstract

introductionThere are currently no established effective additional substrate ablation strategies beyond pulmonary vein isolation (PVI) for persistent atrial fibrillation (AF).

objectiveThis randomized clinical trial evaluated the efficacy of a novel substrate ablation technique using the ExTRa Mapping system, which visualizes rotational activation during AF rhythm.

methodsThis study included 80 patients undergoing initial catheter ablation for persistent AF. Eighty patients whose AF persisted after PVI and ExTRa Mapping were randomly assigned in a 1:1 ratio to either PVI alone or PVI plus ExTRa Mapping-guided substrate ablation targeting areas with high non-passively activated ratio(%NP)( ≥ 35%)(ExTRa group). The primary outcome measure was recurrence of atrial tachyarrhythmias after a 90-day blanking period postablation.

resultsPost-PVI ExTRa Mapping assessed a median of 36 sites per patient in both atria. Baseline characteristics were comparable between groups. The ExTRa group showed higher event-free survival from the primary outcome compared to the PVI alone group (85.0% vs. 67.5% at 1-year, p = 0.07). This favorable prognosis was more pronounced for patients with a large( ≥ 12 sites) area of rotational activation area (81.0% vs. 57.9% at 1-year, p = 0.01). Multivariable analysis identified the number of high %NP areas as an independent risk factor for recurrent tachyarrhythmias (HR 1.13, 95%CI 1.03-1.23, p = 0.005), while ExTRa Mapping-guided substrate ablation emerged as a unique protective factor (HR 0.38, 95%CI 0.13-0.99, p = 0.047).

conclusionWhile the reduction in atrial tachyarrhythmia recurrence of persistent AF patients did not reach statistical significance, the addition of ExTRa Mapping™-guided substrate ablation beyond PVI demonstrated promising potential, especially in patients with larger rotational activation areas.

Indexed as

Atrial FibrillationCatheter AblationElectrophysiologic Techniques, CardiacPulmonary VeinsAction PotentialsAgedFemaleHeart RateHumansMaleMiddle AgedPredictive Value of TestsProgression-Free SurvivalRecurrenceRisk FactorsTime Factorsatrial fibrillationatrial fibrillation drivercatheter ablationExTRa mappingpersistent atrial fibrillation

Identifiers

PMID40548679
PMCPMC12337631

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.